false 0001174940 0001174940 2025-02-17 2025-02-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

 

Date of Report: February 17, 2025

(Date of earliest event reported)

 

 

 

Oragenics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

FL   001-32188   59-3410522

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

 

1990 Main Street

Suite 750

Sarasota, FL

   34236
(Address of principal executive offices)   (Zip Code)

 

813-286-7900

(Registrant’s telephone number, including area code)

 

 

(Former Name or Former Address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   OGEN   NYSE American

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.08 Shareholder Director Nominations

 

On February 17, 2025, the Board of Directors of Oragenics, Inc. (the “Company”) determined it is in the best interest of the Company to schedule Company’s 2024 Annual Meeting of Shareholders (the “2024 Annual Meeting”) for May 16, 2025. Because the date of the 2024 Annual Meeting has advanced by more than 30 days from the anniversary date of the Company’s 2023 Annual Meeting of Shareholders (the “2023 Annual Meeting”), in accordance with Rule 14a−5(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is informing shareholders of such change. The record date, time and location of the 2024 Annual Meeting will be as set forth in the Company’s proxy statement for the 2024 Annual Meeting.

 

Because the date of the 2024 Annual Meeting has been changed by more than 30 days from the anniversary of the 2023 Annual Meeting of Shareholders, a new deadline has been set for submission of proposals by Shareholders intended to be included in the Company’s 2024 proxy statement and form of proxy. Proposals to be included in the Company’s proxy statement for the 2024 Annual Meeting in accordance with Rule 14a-8 under the Exchange Act must be received by the Company on or before March 14, 2025, which the Company believes is a reasonable time before it expects to begin to print and send its proxy materials. Shareholders must deliver the proposals or nominations to the Company’s principal executive offices at the following address: Oragenics, Inc., Attn: Corporate Secretary, 1990 Main Street, Suite 750, Sarasota, Florida 34236.

 

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

 

(d) Exhibits

 

Exhibit No.   Description
     
104   Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL)

 

 

 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 18th day of February, 2025.

 

 

ORAGENICS, INC.

  (Registrant)
   
  BY: /s/ Janet Huffman
   

Janet Huffman

    Chief Financial Officer

 

 

 

v3.25.0.1
Cover
Feb. 17, 2025
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Feb. 17, 2025
Entity File Number 001-32188
Entity Registrant Name Oragenics, Inc.
Entity Central Index Key 0001174940
Entity Tax Identification Number 59-3410522
Entity Incorporation, State or Country Code FL
Entity Address, Address Line One 1990 Main Street
Entity Address, Address Line Two Suite 750
Entity Address, City or Town Sarasota
Entity Address, State or Province FL
Entity Address, Postal Zip Code 34236
City Area Code 813
Local Phone Number 286-7900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol OGEN
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
Oragenics (AMEX:OGEN)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025 Oragenics 차트를 더 보려면 여기를 클릭.
Oragenics (AMEX:OGEN)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025 Oragenics 차트를 더 보려면 여기를 클릭.